Molecule Information

General Information of the Molecule (ID: Mol01188)

• Name: Cytochrome P450 family 3 subfamily A (CYP3A) ,Homo sapiens
• Molecule Type: Protein
• Gene Name: CYP3A

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Drug

Approved Drug(s) 2 drug(s) in total

Darunavir

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Disease Class: Human immunodeficiency virus infection [1]

• Sensitive Disease: Human immunodeficiency virus infection [ICD-11: 1C62.0]
• Sensitive Drug: Darunavir
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Darunavir, a HIV PI that is co-administered with low-dose ritonavir (darunavir/ritonavir), is recommended in combination with other antiretrovirals. The mechanism of ritonavir pharmacokinetic enhancement is through inhibiting cytochrome P450 (CYP) 3A. Ritonavir has intrinsic antiviral activity against HIV-1 when administered at high doses (i.e., 600 mg twice daily) and was the second PI to be licensed. Along with saquinavir and indinavir, it heralded the advent of highly active antiretroviral therapy.

Oxycodone

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Disease Class: Osteosarcoma [2]

• Resistant Disease: Osteosarcoma [ICD-11: 2B51.0]
• Resistant Drug: Oxycodone
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• Mechanism Description: Oxycodone is a semisynthetic opioid receptor agonist, and is frequently used for pain control in patients with cancer. Most oxycodone is metabolized by N-demethylation to noroxycodone by CYP3A. Rifampin is a strong inducer of several drug-metabolizing enzymes, including CYP3A. Hence, rifampin-induced CYP3A activity may decrease the effect of oxycodone.

References

• Ref 1: Darunavir/cobicistat once daily for the treatment of HIV. Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400.
• Ref 2: Oxycodone Resistance Due to Rifampin Use in an Osteosarcoma Patient with Tuberculosis .Am J Case Rep. 2017 Oct 24;18:1130-1134. doi: 10.12659/ajcr.905637. 10.12659/ajcr.905637